AN2 Therapeutics, Inc. - Common Stock, $0.00001 par value per share (ANTX)

Historical Holders from Q1 2022 to Q1 2025

Symbol
ANTX on Nasdaq
CUSIP
037326105
Type / Class
Equity / Common Stock, $0.00001 par value per share
Shares outstanding
30M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
14.5M
Holdings value
$20M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
37
Number of buys
20
Number of sells
-13
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of AN2 Therapeutics, Inc. - Common Stock, $0.00001 par value per share (ANTX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BML Investment Partners, L.P. 19.2% $7.93M 5.75M BML Investment Partners, L.P. Dec 31, 2024
Adjuvant Global Health Technology Fund, L.P. 7.9% $2.75M 2.37M Adjuvant Capital GP, L.P. Dec 31, 2024
Easom Eric 6.2% $2.61M 1.89M Eric Easom Dec 31, 2024
Brii Biosciences Ltd 3.1% $1.28M 927K Brii Biosciences Limited Dec 31, 2024

Institutional Holders of AN2 Therapeutics, Inc. - Common Stock, $0.00001 par value per share (ANTX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 19K $25.8K -$89.1K $1.36 1
2024 Q4 14.5M $20M +$893K $1.38 37
2024 Q3 13.5M $14.5M -$16.3M $1.07 31
2024 Q2 19.4M $41.7M +$374K $2.15 45
2024 Q1 1.58M $5.12M -$15M $3.25 3
2023 Q4 20.4M $418M +$9.58M $20.49 51
2023 Q3 19.9M $320M +$133M $16.08 37
2023 Q2 11.7M $99.9M +$18.1M $8.50 30
2023 Q1 9.6M $94.8M -$1.67M $9.87 37
2022 Q4 9.76M $93M -$3.68M $9.53 35
2022 Q3 9.46M $164M +$2.1M $17.38 34
2022 Q2 9.29M $71.6M +$2.31M $7.75 28
2022 Q1 8.95M $134M +$134M $15.07 17